Patents by Inventor Bharathi Pandi
Bharathi Pandi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230100692Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: ApplicationFiled: November 21, 2022Publication date: March 30, 2023Inventors: Jason D. SPEAKE, Joe S. PERALES, Brent Christopher BECK, Bharathi PANDI
-
Publication number: 20230029009Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.Type: ApplicationFiled: September 6, 2022Publication date: January 26, 2023Inventors: Jason D. SPEAKE, Brent Christopher BECK, Bharathi PANDI, Jennifer C. FREEMAN
-
Patent number: 11512088Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: GrantFiled: January 29, 2020Date of Patent: November 29, 2022Assignee: AVISTA PHARMA SOLUTIONS, INC.Inventors: Jason D. Speake, Joe B. Perales, Brent Christopher Beck, Bharathi Pandi
-
Patent number: 11459331Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.Type: GrantFiled: January 29, 2020Date of Patent: October 4, 2022Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Brent Christopher Beck, Bharathi Pandi, Jennifer C. Freeman
-
Publication number: 20200270257Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.Type: ApplicationFiled: January 29, 2020Publication date: August 27, 2020Inventors: Jason D. Speake, Brent Christopher BECK, Bharathi PANDI, Jennifer C. FREEMAN
-
Patent number: 10744136Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.Type: GrantFiled: November 4, 2019Date of Patent: August 18, 2020Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Bharathi Pandi, Joe B. Perales, Weiming Fan
-
Publication number: 20200239481Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: ApplicationFiled: January 29, 2020Publication date: July 30, 2020Inventors: Jason D. Speake, Joe B. PERALES, Brent Christopher BECK, Bharathi PANDI
-
Publication number: 20200148693Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the invention, which are EP4 receptor antagonists.Type: ApplicationFiled: January 17, 2020Publication date: May 14, 2020Inventors: Jason D. SPEAKE, Bharathi PANDI, Cyprian O. OGBU, Brent Christopher BECK
-
Publication number: 20200138811Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus Kinase inhibitors and are useful in the treatment or control of pruritus, associated with allergic dermatitis, atopic dermatitis in animals, and other disorders and indications where immunosuppression/immunomodulation would be desirable. Also described herein are methods of treating pruritus and atopic dermatitis by administering the compounds of the invention, which are JAK 1 inhibitors.Type: ApplicationFiled: November 4, 2019Publication date: May 7, 2020Inventors: Jason D. SPEAKE, Bharathi PANDI, Joe B. PERALES, Weiming FAN
-
Patent number: 10556909Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: GrantFiled: May 17, 2017Date of Patent: February 11, 2020Assignee: Avista Pharma Solutions, Inc.Inventors: Jason D. Speake, Bharathi Pandi, Cyprian O. Ogbu, Jeffrey A. Adams, Joseph A. Moore, III, Joe B. Perales, Keqiang Li
-
Publication number: 20190284199Abstract: The present disclosure describes a synthetic process and novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives having an isothiazoline moiety, which are useful as antiparasitics.Type: ApplicationFiled: May 17, 2017Publication date: September 19, 2019Inventors: Jason D Speake, Bharathi Pandi, Cyprian O. Ogbu, Jeffrey A. Adams, Joseph A. Moore, III, Joe B. Perales, Keqiang Li
-
Patent number: 8614221Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: March 10, 2010Date of Patent: December 24, 2013Assignees: Merck Sharp & Dohme Corp., MSD K.K.Inventors: Weiming Fan, Thomas F. N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
-
Publication number: 20120004240Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.Type: ApplicationFiled: March 3, 2010Publication date: January 5, 2012Inventors: Weiming Fan, Thomas F.N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
-
Publication number: 20110183975Abstract: The present invention relates to a compound of formula I: wherein: R1 is C1-6 alkyl, C3-8 cycloalkyl, aryl, heterocyclyl, or —COR1x, where the C1-6 alkyl, C3-8 cycloalkyl, aryl, and heterocyclyl may be substituted; and R1x is C3-8 cycloalkyl, aryl, or heterocyclyl, any of which may be substituted; R2, R3, R4, R5, R6, and R7 are each independently hydrogen, halogen, C1-6 alkyl, or aryl, where the C1-6 alkyl or aryl may be substituted; R8 is hydrogen, C1-6 alkyl, aryl, or heterocyclyl, any of which may be substituted; or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: September 28, 2009Publication date: July 28, 2011Inventors: Yasuhiro Goto, Takeshi Sagara, Weiming Fan, Thomas F. N. Hacell, Matthew G. Jenks, Michael J. Malaska, Joseph A. Moore, III, Gilles Ouvry, Bharathi Pandi, Michael R. Peel, Kimberty M. Steward